Hydroquinone, a topical skin-lightening compound, fades unwanted dark pigment. Its best-supported use is melasma, patchy facial darkening, where it works about as well as newer ingredients, and better combined with a vitamin A cream and mild steroid; it also fades sun-induced age spots. Irritation is common and usually mild; a rare, hard-to-reverse blue-black discoloration appears mostly with strong, unsupervised, years-long use. Results depend on sun protection and time-limited courses. (Full Review)

Protocol

Standard monotherapy

4% cream once nightly

2% for sensitive skin; thin layer on affected areas for 8–12 weeks, then reassessment

Triple-combination cream (Tri-Luma)

Once nightly, up to 8 weeks

Hydroquinone 4%, tretinoin 0.05%, fluocinolone 0.01%; only FDA-approved hydroquinone product, for moderate-to-severe facial melasma

Time of day

Evening application

Avoids daytime ultraviolet exposure of freshly treated skin and leaves mornings for sunscreen

Time to effect

Visible lightening

4–8 weeks

Label advises stopping if no improvement appears after 2 months

Peak lightening

Around 12 weeks

Relapse after stopping is common

Age spots

Slower than typical lightening

Frequently need cryotherapy or laser in addition to cream

Benefits

High: Lightening of Melasma; Fading of Sun-Induced Mottled Pigmentation and Age Spots

Low: Fading of Post-Inflammatory Hyperpigmentation; Smoother Texture and Fewer Fine Lines with Retinoid Co-Therapy; Prevention of Procedure-Related Darkening

Contraindications

Pregnancy or breastfeeding (safety not established)

Children younger than 12 years

Prior allergic reaction to hydroquinone or any product ingredient, including sulfite allergy or sulfite-sensitive asthma for metabisulfite-containing products

History of exogenous ochronosis (blue-black skin darkening) or hydroquinone-induced leukoderma (patchy loss of skin color)

Fitzpatrick types V–VI (darkest skin types) planning concentrations above 4% or continuous use beyond 3 months without supervision

Broken, sunburned, eczema-affected or freshly shaved skin at the application site

Key Interactions

Topical retinoids (tretinoin, tazarotene, adapalene): caution, additive redness and peeling

Benzoyl peroxide and hydrogen peroxide (over-the-counter acne and bleaching products): caution, transient dark skin staining

Photosensitizing drugs (doxycycline, hydrochlorothiazide, isotretinoin): monitor, heightened sun sensitivity

Estrogen-containing drugs (ethinyl estradiol, estradiol, conjugated estrogens): monitor, can blunt response

Topical corticosteroids (fluocinolone, clobetasol, mometasone): caution, prolonged facial use causes thinning and small visible dilated vessels

Exfoliating acids (glycolic acid, salicylic acid, resorcinol): caution, additive irritation and risk of post-inflammatory darkening

Arbutin or bearberry (uva-ursi) supplements and serums: monitor, adding hydroquinone exposure

Supplements with additive lightening (Polypodium leucotomos, glutathione) and oral tranexamic acid: monitor, additive pigment reduction

Lasers, chemical peels and microneedling: caution, raised darkening risk

Risk & Side Effects

High: Skin Irritation and Contact Dermatitis

Medium: Exogenous Ochronosis

Low: Confetti-Like Depigmentation and Paradoxical Darkening; Nail Discoloration; Exposure to Adulterated Lightening Products; Steroid Effects from Triple-Combination Creams

Speculative: Carcinogenicity and DNA Damage; Fetal Exposure During Pregnancy

Monitoring

Marker	Target	Why
mMASI score	At least 50% reduction from own baseline by week 12	Tracks melasma response
Colorimetric lightness (L*) or melanin index	No established target; track change from own baseline	Objective pigment change
24-hour test-site reaction	No itching, blistering or swelling	Detects allergy before full use
Dermoscopy of treated skin	No blue-gray globules or "caviar-like" dark papules	Early ochronosis detection
Pregnancy test (hCG)	Negative	Avoids fetal exposure
Urine mercury	Below 5 µg/L	Screens for mercury-adulterated creams; only if unregulated lighteners were used

Cadence: Baseline before starting; at 4, 8 and 12 weeks during the first course, then every 3 months while treatment continues, and again at each restart after a break; dermoscopy every 3–6 months for courses beyond 3 months

Qualitative Assessment

Evenness of skin tone in daylight photographs
Fewer visible age spots
Comfortable skin without stinging or peeling
Satisfaction with appearance and makeup use

Hydroquinone for Skin Rejuvenation

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment